The civic record
Read. Follow. Verify.Iowa Senate Bill 2154 imposes safety study mandates, fines, and manufacturer liability for gene-based vaccines
Last action · February 4, 2026: Subcommittee: Sweeney, Petersen, and Webster. S.J. 199 .Sponsor: Doug Campbell
Track this bill to get notified when it advances a stage. One tap to stop, anytime.
What This Bill Would Do
Iowa Senate File 2154 requires manufacturers of s to complete transmissibility, DNA contamination, and studies before distribution in the state. The measure establishes a $1,000 fine per occurrence and potential license discipline for distributors of vaccines posing an unreasonable health risk as determined by the FDA, removes liability immunity for vaccine manufacturers regarding design defects, and directs the department of inspections, appeals, and licensing to adopt enforcement rules.
Vaccine manufacturers and distributors face new mandatory pre-distribution research requirements, state civil penalties of $1,000 per violation, potential loss of professional licensing, and exposure to personal injury or wrongful death lawsuits stemming from design defects.
- Senate File 2154 was introduced in the Iowa Senate by Senator Campbell during the 91st General Assembly session. context
Who It Would Affect
Groups the bill's text would affect if enacted, as described in the record. Being affected is not a position for or against it.
Gene-based vaccine manufacturers
Manufacturers must complete specific transmissibility, DNA contamination, and shedding studies before distribution, lose liability immunity for design defects, and are subject to state rules.
Vaccine distributors
Distributors face a $1,000 fine per occurrence and potential license discipline if they distribute a gene-based vaccine determined by the FDA to pose an unreasonable public health risk.
Department of Inspections, Appeals, and Licensing
The agency is required to promulgate administrative rules to enforce and administer the new restrictions and penalties.
Key Facts
- Manufacturers must conduct integrative transmissibility, DNA contamination, and shedding studies prior to distributing any gene-based vaccine in Iowa.
- Distributors of a gene-based vaccine that poses an unreasonable risk of harm to public health through transmission or shedding, as determined by the FDA, are subject to a $1,000 fine per occurrence and potential licensee discipline.
- Manufacturers that distribute, sell, or use a gene-based vaccine in the state lose immunity from legal liability arising from injury or death caused by a design defect.
- The department of inspections, appeals, and licensing is directed to promulgate rules pursuant to chapter 17A to enforce and administer the section.
Show all 7 facts
- The bill defines deoxyribonucleic acid contamination as unintended residual DNA fragments remaining in a manufactured gene-based vaccine.
- Gene-based vaccines are defined to include vaccines developed using messenger ribonucleic acid technology, modified mRNA technology, self-amplifying mRNA technology, or DNA technology.
- Shedding is defined as the process by which weakened components of a vaccine are released from a vaccinated individual into the environment.
Frequently Asked Questions
What studies must a manufacturer complete before distributing a gene-based vaccine in Iowa?
Can vaccine manufacturers be sued for design defects under this bill?
What is the penalty for distributing a gene-based vaccine that poses an unreasonable health risk?
What else do you want to know?
News Coverage
Follow the record
Votes, people, money & the original sourceWhere This Stands
Currently in committee. The next step in the legislative lifecycle is Floor Vote.
Procedural history
2 actions- Feb 4, 2026SenateSubcommittee: Sweeney, Petersen, and Webster. S.J. 199 .
- Jan 29, 2026SenateIntroducedIntroduced, referred to Health and Human Services. S.J. 168 .
Version history
Only one version on file - nothing to compare yet. As later stages (committee substitute, engrossed, enrolled) are captured, the redline appears here.
View official text →Lobbying Activity
No state lobbying filings in our records match this bill. Federal lobbying reports (LDA) cover Congress, so they are not listed on state bills.
Full breakdown
Who this bill affects and the strongest case for and against it, written only from the bill’s own text.
Sponsors
Discoveries
Patterns POLISCOPE noticed across the record. These are observations to investigate, not conclusions.
State-Level Vaccine Liability Removal
The bill explicitly overrides standard liability protections by stating manufacturers are not immune from design defect injuries or deaths within the state.
Connected Entities
Sources
www.legis.iowa.gov
Analysis Score
0–100- Significance75How much this matters to a regular citizen
- Controversy85Intensity of disagreement among stakeholders
- Entertainment10Compellingness for a non-policy-wonk reader
- Buzz60Current news / social attention level
Publisher tools